✦ LIBER ✦

Pharmacokinetics of pyropheophorbide-a-hexyl ether in the dog

✍ Scribed by Payne, John T.; McCaw, Dudley L.; Casteel, Stan W.; Frazier, Donita; Rogers, Kevin; Tompson, Robert V.

Publisher: John Wiley and Sons
Year: 1996
Tongue: English
Weight: 331 KB
Volume: 18
Category: Article
ISSN: 0196-8092
DOI: 10.1002/(sici)1096-9101(1996)18:4<406::aid-lsm10>3.0.co;2-1

No coin nor oath required. For personal study only.

✦ Synopsis

Background and objectiues. Pyropheophorbide-a-hexyl ether (HPPH) is a new compound being investigated for use as a photosensitizer for photodynamic therapy; however, the pharmacokinetics are not known for any of the target species likely to be treated with this drug. The objective of this study was to determine the pharmacokinetic parameters of this drug prior to institution of a clinical trial in canine patients with various cancers. Study design, Materials and Methods. HPPH (0.3mgkg I.V.) was administered to 12 dogs and blood samples were drawn at intervals for 24 hours and plasma HPPH concentrations were determined. Pharmacokinetic parameters were calculated for each dog.

Results. No evidence of toxicity was noted in any dog. The mean half-life was calculated to be 26.98 f 2.35 hrs. The mean clearance was 5.061 * 0.214 ml/hr/kg. The mean volume of distribution of the central compartment was 0.069 2 0.003 L/kg, and the mean steady state volume of distribution was 4.47 +: 0.25 Lkg. Conclusion. The conclusion is that 0.3 mgkg HPPH injected intravenously resulted in measurable plasma levels for 24 hrs, and resulted in no detectable adverse reactions.

📜 SIMILAR VOLUMES

Pharmacokinetics of reboxetine enantiome

Pharmacokinetics of reboxetine enantiomers in the dog

✍ E. Frigerio; A. Benecchi; G. Brianceschi; C. Pellizzoni; I. Poggesi; M. Strolin 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 2 views

Reboxetine, (RS)-2-[(RS)-alpha-(2-ethoxyphenoxy)benzyl]morpholine methanesulphonate, is a racemic compound and consists of a mixture of the (R,R)- and (S,S)-enantiomers. The pharmacokinetics of reboxetine enantiomers were determined in a crossover study in three male beagle dogs. Each animal receive

Interspecies pharmacokinetic scaling of

Interspecies pharmacokinetic scaling of a new carbapenem, DA-1131, in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics

✍ So H. Kim; Won B. Kim; Myung G. Lee 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB 👁 1 views

The total body clearance (CI), renal clearance (CIr), and apparent volume of distribution at steady state (Vss) of DA-1131, a new carbapenem, after intravenous (iv) administration of the drug, 50 mg kg-1, to mice, rats, rabbits, and dogs were analysed as a function of species body weight (W) using t

Pharmacokinetic evaluation in dogs of th

Pharmacokinetic evaluation in dogs of theophylline in a novel zero-order release core-in-cup tablet

✍ Michael P. Danckwerts; Jakkie G. van der Watt; Indres Moodley 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB 👁 1 views

A new core-in-cup tablet that is manufactured from a novel adjustable punch, has been formulated and evaluated for its ability to release with subsequent absorption of theophylline via a zero-order rate of absorption. The core-in-cup tablets were compared with core only tablets and immediate release

Plasma pharmacokinetics and tissue biodi

Plasma pharmacokinetics and tissue biodistribution of boron following administration of a boronated porphyrin in dogs

✍ Jay Tibbitts; Nancy C. Sambol; John R. Fike; William F. Bauer; Stephen B. Kahl 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB 👁 1 views

This study was undertaken to determine the plasma pharmacokinetics and tissue biodistribution of boron in dogs following the administration of a boronated porphyrin (BOPP) compound, a potential sensitizing agent for binary therapies of cancer. An intravenous dose of 35 mg/kg of BOPP was administered

Effects of pentobarbital on pharmacokine

Effects of pentobarbital on pharmacokinetics and pharmacodynamics of a potent fibrinogen receptor antagonist, L-734 217, in dogs

✍ T. Prueksaritanont; M. T. Stranieri; E. L. Hand; J. D. Ellis; M. A. Holahan; G. 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 364 KB 👁 1 views

Eects of pentobarbital on pharmacokinetics and pharmacodynamics of L-734 217, a potent ®brinogen receptor antagonist, were studied in male dogs. L-734 217 was given intravenously at 0´01 mg kg 71 , in a cross-over fashion, to conscious dogs or to dogs anesthetized with pentobarbital. Plasma concentr

The pharmacokinetics and metabolism of C

The pharmacokinetics and metabolism of CP-191,166, an angiotensin II receptor antagonist, in rats and dogs

✍ Mary C. Allen; Mark R. Nocerini; Wesley W. Day 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB

166 is an orally active, non-peptide angiotensin II (AII) receptor antagonist developed for the treatment of hypertension and congestive heart failure (CHF). In this study, the intravenous (iv) and oral (po) single dose pharmacokinetics (PK), oral multiple dose PK and P450-mediated metabolism of 16